L and J-HZ by L&J Bio for Herpes Zoster (Shingles): Likelihood of Approval

L and J-HZ is under clinical development by L&J Bio and currently in Phase I for Herpes Zoster (Shingles).

Adaptimmune loses $3B biobucks pact with Genentech

Roche’s Genentech has broken off its collaboration and license agreement on off-the-shelf T cell therapies with Adaptimmune. The pullback means Adaptimmune could miss out on

April 13, 2024

Pharmalittle: Curevac loses key patent in battle with BioNTech; Abernethy to step down as Verily CMO

Good morning, everyone, and how are you today? We are doing just fine, thank you. Given that this is already the middle of the week

December 20, 2023

Lipidomics and metabolomics as potential biomarkers for breast cancer progression

This review highlights the potential of lipidomic and metabolomic biomarkers in predicting breast cancer prognosis and therapy response, enhancing patient care.

September 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.